Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.50 |
| ▸ | TDO2 | P48775 | 7/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GABRP | O00591 | 1/20 | 0.46 |
| ▸ | GABRD | O14764 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.46 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26259560 | 0.78 | PDPK1 (0.54) | CYP1A2HSD17B10METAP1PDPK1 | |
| SCHEMBL28267452 | 0.77 | TDO2 (0.45) | BCHETDO2KDM4EMEN1GABRP | |
| SCHEMBL29733506 | 0.76 | KIF11 (0.63) | BCHEGABRPGABRDALDH1A1GABRA1 | |
| SCHEMBL208113 | 0.76 | KIF11 (0.63) | BCHEGABRPGABRDALDH1A1GABRA1 | |
| SCHEMBL14119773 | 0.76 | BCHE (0.56) | BCHETDO2KDM4EMEN1GABRP | |
| SCHEMBL29986379 | 0.76 | BCHE (0.56) | BCHETDO2KDM4EMEN1GABRP | |
| SCHEMBL28372320 | 0.75 | PARP14 (0.47) | BCHETDO2KIF11PARP14 | |
| SCHEMBL27470497 | 0.75 | METAP1 (0.42) | MEN1CYP1A2CYP3A4CYP2D6MAPT | |
| SCHEMBL149958 | 0.74 | BCHE (0.55) | BCHETDO2KDM4EMEN1GABRP | |
| SCHEMBL29986103 | 0.74 | BCHE (0.55) | BCHETDO2KDM4EMEN1GABRP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108169189-A | A kind of response sulfur dioxide/sulfurous acid（Hydrogen）The ratio fluorescent probe of salt | 济南大学 | 2018-06-15 | — | — | CN | claimed |
| CN-110156773-A | It is a kind of detect sulfur dioxide Ratiometric fluorescent probe and its application | 济南大学 | 2019-08-23 | — | — | CN | disclosed |
| US-8362065-B2 | Carbazole carboxamide compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-29 | — | — | US | disclosed |
| CN-102812573-A | Materials for organic electroluminescent devices | MERCK PATENT GMBH | 2012-12-05 | — | — | CN | disclosed |
| US-20120058996-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-03-08 | — | — | US | disclosed |
| US-8084620-B2 | Carbazole carboxamide compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-12-27 | — | — | US | disclosed |
| US-20100160303-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-06-24 | — | — | US | disclosed |
| CN-1768745-A | Medicine for improving excretion capacity of bladder | TAKEDA PHARMACEUTICAL (JP) | 2006-05-10 | — | — | CN | disclosed |
| CN-1572299-A | Medicine for improving excretion capacity of bladder | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2005-02-02 | — | — | CN | disclosed |
| CN-1535682-A | Medicine for improving excretion capacity of bladder | ����ҩƷ��ҵ��ʽ���� | 2004-10-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058996-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BTK, FLT3, JAK1 | BCHE 2124/4885TDO2 2235/4885KDM4E 733/4885 |
| US-20100160303-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BTK, FLT3, JAK1 | BCHE 2124/4885TDO2 2235/4885KDM4E 733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.